154590-65-5

Usage

Molecular weight

391.39 g/mol

Chemical structure

An ester derivative of piperazinecarboxylic acid with a 4-(4-oxazolidinone) and 2-fluorophenyl ring substitution.

Pharmacological properties

Potential as an antiviral agent, particularly against HIV, due to its ability to inhibit the viral protease enzyme. Exhibits antibacterial and antifungal properties.

Therapeutic potential

Promise as a candidate for the development of new antimicrobial drugs. May have potential for use in the treatment of cancer or autoimmune diseases.

Need for further research

To fully explore its pharmacological properties and potential therapeutic uses.

Upstream product

• 268209-15-0 tert-butyl 4-(4-((S)-5-(aminomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazine-1-carboxylate 
• 108-24-7 acetic anhydride 
• 369-34-6 3,4-difluoronitrobenzene 
• 154590-64-4 (S)-N-[3-[3-fluoro-4-[N-t-butoxycarbonylpiperazin-1-yl]phenyl]-2-oxooxazolidin-5-ylmethyl]azide 
• 183905-31-9 N-[(2S)-2-acetoxy-3-chloropropyl]acetamide 
• 154590-33-7 1-(2-fluoro-4-nitrophenyl)piperazine 
• 154590-36-0 tert-butyl 4-(4-(benzyloxycarbonyl)-2-fluorophenyl)piperazine-1-carboxylate 
• 154590-62-2 (R)-tert-butyl-4-(2-fluoro-4-(5-(hydroxymethyl)-2-oxooxazolidin-3-yl)phenyl)piperazine-1-carboxylate 
• 154590-34-8 4-(2-fluoro-4-nitrophenyl)-piperazine-1-carboxylic acid tert butyl ester 
• 154590-35-9 tert-butyl 4-(4-amino-2-fluorophenyl)piperazine-1-carboxylate 
• 154590-63-3 [N-3-(1-tert-butoxycarbonyl)-4-(2-fluoro-4-piperazinyl)-2-oxo-5-oxazolidinyl]methyl methanesulfonate 

Downstream Products

• 665011-78-9 (S)-N-[3-[3-fluoro-4-(4-(4-nitrophenyl)carbamidopiperazin-1-yl)phenyl]-2-oxooxazolidin-5-methyl]acetamide 
• 665011-62-1 tert-butyl-(S)-(2-(4-(4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-2-oxoethyl)carbamate 
• 548762-73-8 N-[3-(3-fluoro-4-{4-[5-(hydroxyimino-methyl)-furan-2-ylmethyl]-piperazin-1-yl}-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide 

Relevant academic research and scientific papers

Oxazolidinone compound containing piperazine hydrazone structure

The invention discloses an oxazolidinone compound containing a piperazine hydrazone structure. The oxazolidinone compound comprises a compound shown as a general formula (I), or stereisomer thereof, or pharmaceutically-acceptable salt thereof, or solvate thereof or prodrug thereof, wherein R1 is hydrogen, fluorine, chlorine or trifluoromethyl, R2 is -NHCOCH3 or -OH, R3 is Ar which is C5-C10 aryl substituted by any 1-3 R4 and heteroaryl, and R4 is hydrogen, hydroxyl, halogen, nitro, amino, cyan, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl substituted by hydroxyl, amino or halogen, C1-C6 alkoxy substituted by hydroxyl, amino or halogen, amino substituted by mono- or bi-(C1-C6 alkyl), C1-C6 alkyl amido, free, salty, esterified and amidated hydroxyl, C1-C6 alkyl sulfinyl, C1-C6 alkyl sulfonyl, C1-C6 alkyl acyl and carbamoyl. The oxazolidinone compound can be used for preparing drug for treating microbial infection.

Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents

Novel oxazolidinone antibacterials bearing a variety of 3-indolylglyoxamide substituents have been explored in an effort to improve the spectrum and potency of this class of agents. A subclass of this series was also made with the diversity at C-5 terminus. These derivatives have been screened against a panel of clinically relevant Gram-positive pathogens and fastidious Gram-negative organisms. Several analogs in this series were identified with in vitro activity superior to linezolid (MIC = 0.25-2 μg/mL). Compounds 10a, 10c, 10e and 10f displayed activity against linezolid resistant Gram-positive organisms (MIC = 2-4 μg/mL). Selected oxazolidinones were evaluated for in vivo efficacy against a mouse systemic infection model.

Synthesis and SAR of novel oxazolidinones: Discovery of ranbezolid

Novel oxazolidinones were synthesized containing a number of substituted five-membered heterocycles attached to the 'piperazinyl-phenyl-oxazolidinone' core of eperezolid. Further, the piperazine ring of the core was replaced by other diamino-heterocycles.

NOVEL ANTIBACTERIAL AGENTS

The present invention provides novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and phar